Organisation paid for research Program year 2025 Source: CMS Open Payments

Aboutskin Research LLC

Neither a doctor nor a teaching hospital

Research payments

$531,009

43 payments

Through program year 2025, Aboutskin Research LLC is reported as receiving $531,009 in research payments, across 43 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$39,867	3
2024	Research	$1,663	2
2023	Research	$187,546	20
2022	Research	$301,733	17
2019	Research	$200	1

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $519,231 37 payments
Pfizer Inc. $11,078 4 payments
Endo Pharmaceuticals Inc. $700 2 payments

Studies the money was for Research payments · program years 2019–2025

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $342,126 23 payments
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines $131,176 11 payments
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation $30,846 1 payment
A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $11,078 4 payments
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder $7,770 1 payment
A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder $7,313 1 payment
A Phase 2B, Open-Label Long-Term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite) $500 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy Cellulite $200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.